In the BioHarmony Drug Report Database

"Preview" Icon

Cenobamate

Xcopri, Ontozry (cenobamate) is a small molecule pharmaceutical. Cenobamate was first approved as Xcopri on 2020-03-10. It is used to treat partial epilepsies in the USA. It has been approved in Europe to treat epilepsy. It is known to target gamma-aminobutyric acid receptor subunit alpha-4 and gamma-aminobutyric acid receptor subunit alpha-6. Xcopri maintenance pack’s patent is valid until 2027-10-30 (FDA).

 

Trade Name

 

Ontozry
 

Common Name

 

cenobamate
 

ChEMBL ID

 

CHEMBL3989949
 

Indication

 

epilepsy, partial epilepsies
 

Drug Class

 

Tranquilizers/antiepileptics (propanediol and pentanediol groups)

Image (chem structure or protein)

Cenobamate structure rendering